Navigation Links
Response Biomedical Corporation Reports 2007 Financial Results
Date:3/31/2008

ted States securities regulatory authorities.

Given these uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward-looking statements or information. We disclaim any obligation to update, or to publicly announce any revisions to, any such statements or information to reflect future results, events or developments.

CONTACT: Bill Wickson, Manager, Investor Relations, Response Biomedical Corporation, Tel (604) 456-6073, Email: bwickson@responsebio.com; Brian Korb, Vice President, The Trout Group LLC, Tel: (646) 378-2923, Email: bkorb@troutgroup.com


'/>"/>
SOURCE Response Biomedical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Study identifies key player in the bodys immune response to chronic stress
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
5. Merck & Co., Inc. Response to Todays New York Medicaid Suit
6. Maternal depression and controlling behavior associated with increased stress response in infants
7. Family history of alcoholism affects response to drug used to treat heavy drinking
8. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
9. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...ive alternative to conventional angiography for ev...nary artery disease; true even if the patients hav...a study performed at the Thomas Jefferson Universi...ded 31 patients who had one or more calcified coro...ronary CTA. Calcified plaques in the arteries were...
(Date:12/1/2008)... during molecular breast imaging (MBI) can accurat...ize, according to a study performed at the Mayo Cl...ents who had suspicious lesions smaller than 2 cm ...st imaging. "There were 128 cancers confirmed in 8...ad author of the study. "The sensitivity rate of d...
(Date:12/1/2008)...wn that babies exposed to tobacco in utero are mor...reased risk for sudden infant death syndrome. Now ...hese babies are also less likely to self-soothe an...se mothers did not smoke during pregnancy. , Res...havioral and Preventive Medicine say early identif...
(Date:12/1/2008)... microscopic crystals form sound and gravity senso...lia tiny cellular hairs in the ear that move and ... role in detecting sound, maintaining balance and ... are to blame for the most common form of vertigo....e disorder plagues up to 10 percent of people olde...
Breaking Medicine News(10 mins):Health News:Newborns exposed to maternal smoking more irritable, difficult to soothe 2Health News:Can you hear me now? How the inner ear's sensors are made 2
...-malarial herbal drug could be damaged by overplan...//, the World Health Organization (WHO) said on Mo...must be more carefully farmed to meet a growing gl...es off the market, the United Nations agency said....
...ople lost an eye each allegedly due to medical neg...cials said the patients// were to blame because th...ct administration had organised a cataract operati...Bhabanipatna town, some 600 km from here. Fifteen ...
...me location for clinical trials for many pharmaceu...ers Squibb, GlaxoSmithkline, Eli Lilly are among t...try. Currently over 226 clinical trials approved ... and Drug Administration (FDA) are in India. Fac...
... that don't cause the pain and bruising common wit...// by a team in California. In a bid to confront ...n by the pain and discomfort experienced by patien...versity of California has developed an alternative...
Other Medicine News:Health News:Malaria-curing Herb Must Be Carefully Farmed - WHO 2Health News:India Fast Become Prime Location for Clinical Trials, but Vigilance Called for 2Health News:Micro-jets for Painless Needle-free Injections 2Health News:Micro-jets for Painless Needle-free Injections 3
(Date:11/24/2008)... Leaders of Schering-Plo...pdate for investors on the company,s research pipe... that includes 46 new entities in clinical trials ...tudies. , , "Research and development is ad... continue our transformation," said Fred Hassan, c...
(Date:11/24/2008)...ovation leadership and long-term commitment to hep...24 Schering-Plough Corpo...date on boceprevir, its lead investigational oral ...III development. The company believes boceprevir ...in-class protease inhibitor for treating chronic h...
(Date:11/24/2008)... Schering-Plough Corpora...t, its novel and selective adenosine2a receptor an...ose-finding trial in patients suffering from moder...or fluctuations and abnormal involuntary movements...today at the company,s 2008 R&D Update meeting...
(Date:11/24/2008)...24 GeneThera, Inc.,(Pin...ffering its Real Time,PCR test for Johne,s diseas... GeneThera is set to begin offering its Johne,s...09. According to GeneThera Chairman, Dr. Tony Mil... time PCR test for Johne,s disease,called HerdGu...
Breaking Medicine Technology:Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4Non Profit Calls on Mental Health Professionals to Honor Veterans Day by Giving an Hour of Free Counseling to Returning Veterans 5998 1Non Profit Calls on Mental Health Professionals to Honor Veterans Day by Giving an Hour of Free Counseling to Returning Veterans 5998 2New Data Presented on the Renessa 28R 29 Treatment for Female Stress Urinary Incontinence 822 1New Data Presented on the Renessa 28R 29 Treatment for Female Stress Urinary Incontinence 822 2New Data Presented on the Renessa 28R 29 Treatment for Female Stress Urinary Incontinence 822 3Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions 818 1Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions 818 2Parents survey 3A Perceptions of the duration of their childs ADHD medication 5994 1Parents survey 3A Perceptions of the duration of their childs ADHD medication 5994 2
...ce Male Sling System is an innovative, safe and ef...ess urinary incontinence in men following prostate...andidates for an artificial urinary sphincter due ...ty or patient preference., ,InVance uses a mes...
...apid, safe, reproducible re-entry of a guidewire f...of a peripheral vessel., , Locate ,Propriet... visibility, facilitates rapid and accurate orient...and eliminates the need for additional equipment,...
...o SET LNOP Blue Sensor is the first sensor designe... sensor is the first and only sensor to receive ac...Cyanotic infants and children have long presented ...ulse oximetry, and Masimo's research team recogniz...
Inquire
Medicine Products: